Page 46 - Read Online

Casas-Alba et al. J Transl Genet Genom 2022;6:322-32 https://dx.doi.org/10.20517/jtgg.2022.03 Page 330

Financial support and sponsorship
Palau & Hoenicka Lab is supported by the Agencia Estatal de Investigación (PID2020-114655RB-100), the
Instituto Salud Carlos III grant DTS16/00196 (F.P.); the Generalitat de Catalunya and European Regional
Development Fund grants SLT002/16/00174 (F.P.), 2015 FEDER/S-21 (F.P.), and SLT002/16/00306 (F.P.);
the Fundación Isabel Gemio (F.P.); CIBERER (F.P.); the Torró Solidari-RAC1 i Torrons Vicens (J.H.); J.P. is
the recipient of the Carmen de Torres contract from the Institut de Recerca Sant Joan de Déu. CIBERER is
an initiative of the Instituto de Salud Carlos III. The IPER is part of the Centre Daniel Bravo de Diagnòstic i
Rercerca en Malalties Minoritàries.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Regulation (EC) No 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products.
European Parliament. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32000R0141 [Last accessed on
9 June 2022].
2. N a t i o n a l I n s t i t u t e o f H e a l t h . P u b l i c l a w 9 7 - 4 1 4 9 7 t h c o n g r e s s . J a n 4 , 1 9 8 3 . A v a i l a b l e f r o m :
https://history.nih.gov/research/downloads/PL97-414.pdf [Last accessed on 9 June 2022].
3. Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet
database. Eur J Hum Genet 2019;28:165-73. DOI PubMed PMC
4. Tisdale A, Cutillo CM, Nathan R, et al. The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare
systems. Orphanet J Rare Dis 2021;16:429. DOI PubMed PMC
5. Graessner H, Zurek B, Hoischen A, Beltran S. Solving the unsolved rare diseases in Europe. Eur J Hum Genet 2021;29:1319-20. DOI
PubMed PMC
6. Austin CP, Cutillo CM, Lau LPL, et al; Future of rare diseases research 2017-2027: an IRDiRC perspective.
Clin Transl Sci 2018;11:21-7. DOI PubMed PMC
7. Seaby EG, Rehm HL, O’Donnell-Luria A. Strategies to uplift novel mendelian gene discovery for improved clinical outcomes. Front
Genet 2021;12:674295. DOI PubMed PMC
8. Kliegman RM, Bordini BJ, Basel D, Nocton JJ. How doctors think: common diagnostic errors in clinical judgment-lessons from an
undiagnosed and rare disease program. Pediatr Clin N Am 2017;64:1-15. DOI PubMed
9. About undiagnosed diseases. Available from: https://www.udninternational.org/schede-38-about_undiagnosed_diseases [Last accessed
on 9 June 2022].
10. Boycott KM, Hartley T, Biesecker LG, et al. A diagnosis for all rare genetic diseases: the horizon and the next frontiers. Cell
2019;177:32-7. DOI PubMed
11. Köhler S, Carmody L, Vasilevsky N, et al. Expansion of the human phenotype ontology (HPO) knowledge base and resources. Nucleic
Acids Res 2019;47:D1018-27. DOI PubMed PMC
12. Yang J, Benyamin B, McEvoy BP, et al. Common SNPs explain a large proportion of the heritability for human height. Nat Genet
2010;42:565-9. DOI PubMed PMC
13. Pijuan J, Rodríguez-Sanz M, Natera-de Benito D, et al. Translational diagnostics: an in-house pipeline to validate genetic variants in
children with undiagnosed and rare diseases. J Mol Diagn 2021;23:71-90. DOI PubMed
14. Palau F. Medicina personalizada o de precisión: la homeostasis de la individualidad. Rev Soc Esp Bioq Biol Mol 2020;8-13. Available
from: https://revista.sebbm.es/pdf.php?id=643 [Last accessed on 9 June 2022].
15. Palau F. Pediatric genomics and precision medicine in childhood. In: Faintuch J, Faintuch S, editors. Precision medicine for
investigators, practitioners and providers. Cambridge: Academic Press, 2020; pp. 143-152. Available from:
https://www.elsevier.com/books/precision-medicine-for-investigators-practitioners-and-providers/faintuch/978-0-12-819178-1 [Last